DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Bone Fracture - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bone Fracture - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Biopharm GmbH Bone Therapeutics SA Entera Bio Ltd. ethris GmbH Hemostemix Inc. Kolon TissueGene Inc. Kuros Biosciences AG Laboratorios SALVAT SA Novartis AG Viking Therapeutics Inc.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Bone Fracture - Overview

4. Bone Fracture - Therapeutics Development

5. Bone Fracture - Therapeutics Assessment

6. Bone Fracture - Companies Involved in Therapeutics Development

7. Bone Fracture - Drug Profiles

8. Bone Fracture - Dormant Projects

9. Bone Fracture - Discontinued Products

10. Bone Fracture - Product Development Milestones

Featured News & Press Releases (2017-2018)

Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/d8jjtf/bone_fracture?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005396/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:48 AM/DISC: 09/14/2018 11:48 AM